Novavax Global Commercial Operations and COVID-19 Vaccine Update

Anti-S IgG GMT with 95% CI IgG responses independent of formulation: No advantage against BA.5 with a BA.1-specific booster Primary series of mRNA vaccines + Novavax booster (Prototype, BA-1 or Bivalent strain) Prototype IgG BA.1 IgG BA.5 IgG 95% VE 90,875 100,000 72,015 76,903 49,827 43,474 42,060 38,353 29,915 31,724 88% VE* 10,000 1,000 100 10 Prototype BA.1 Boost Boost Bivalent Boost novavax Prototype Boost BA.1 Boost Bivalent Boost Prototype Boost BA.1 Boost Bivalent Boost *Correlates of Protection inferred from Fong, Y., et al., 2023. DOI: 10.1038/s41467-022-35768-3 Validated assays performed at Novavax Clinical Immunology, includes all participants © 2023 NOVAVAX. All rights reserved. 55 55 NK

View entire presentation